EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Stefan Christiansen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christiansen, S.
Right arrow Articles by Autschbach, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christiansen, S.
Right arrow Articles by Autschbach, R.
Related Collections
Right arrow Education
Right arrow Congestive Heart Failure

Eur J Cardiothorac Surg 2006;30:611-616
© 2006 Elsevier Science NL

Reviews

Doxorubicin in experimental and clinical heart failure

Stefan Christiansen*, Rüdiger Autschbach

Department of Cardiothoracic Surgery, University of Aachen, Pauwelsstr. 30, 52074 Aachen, Germany

Received 2 January 2006; received in revised form 22 June 2006; accepted 26 June 2006.

* Corresponding author. Tel.: +49 241 80 89221; fax: +49 241 80 82454. (Email: schristiansen{at}ukaachen.de).

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

Key Words: End-stage heart failure • Doxorubicin • Cardiac surgery






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.